Species

Prascend®

(pergolide tablets)

Details

PRASCEND for horses is the most proven treatment available to control the clinical signs associated with PPID in horses.1 Pituitary pars intermedia dysfunction (PPID), also referred to as equine Cushing’s disease, is one of the most common endocrine disorders in horses. Signs of PPID can be subtle, but the disease can be serious. 

 

PRASCEND contains 1 mg pergolide for horses, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only. To find out more about Prascend visit prascend.com.

 

PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. PRASCEND has not been evaluated in breeding, pregnant or lactating horses.

Features & Benefits

Features


  • Most proven treatment for PPID in horses

  • Contains 1 mg pergolide for horses, as pergolide mesylate, a dopamine receptor agonist

  • Single-scored tablets make it simple to adjust dosage

 

Benefits


  • Improved clinical signs within 3 months and continued through 6 months1

  • 3 out of 4 horses evaluated were considered treatment successes1

  • Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months1

 

Dosage & Administration

PRASCEND tablets are available with a prescription by a veterinarian, but can be administered by a horse owner. Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily.

 

PRASCEND tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.

 

For more information please read the PRASCEND Product Insert.

Resources

idppid.com

prascend.com

Prascend Prescribing Information

PPID Management Brochure

Safety

Storage: Store at or below 25°C (77°F).

 

IMPORTANT SAFETY INFORMATION: PRASCEND is for use in horses only. PRASCEND has not been evaluated in breeding, pregnant or lactating horses. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Pregnant or lactating women should wear gloves when administering this product. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Refer to the package insert for complete product information.

References
  1. PRASCEND [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011
Trademarks

PRASCEND® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0125-2021

 

IMPORTANT SAFETY INFORMATION

PRASCEND is for use in horses only. PRASCEND has not been evaluated in breeding, pregnant or lactating horses. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Pregnant or lactating women should wear gloves when administering this product. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Refer to the package insert for complete product information.